查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1570722

成人疫苗市场：按疫苗类型、适应症和最终用户划分 - 全球预测 2025-2030

Adult Vaccines Market by Vaccine Type (Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines), Disease Indication (Hepatitis B, Herpes Zoster, Human Papillomavirus (HPV)), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年成人疫苗市场规模为176.3亿美元，预计2024年将达到191.1亿美元，复合年增长率为8.28%，预计到2030年将达到307.8亿美元。

成人疫苗市场包括用于预防成人感染疾病的疫苗的开拓、生产和应用。由于世界人口老化、可预防疾病意识增强以及政府免疫工作等因素，市场正在应对日益增长的疫苗需求。应用包括流感、脑膜炎、HPV 和肝炎疫苗，最终用途范围从个人健康维护到公共卫生计划。影响成长的关键因素包括政府更加关注卫生政策、疫苗技术的进步以及公众疾病预防意识的提高。疫苗接种率低的新兴市场有许多成长机会，而医疗保健机会的改善将是成长背后的动力。产业公司应专注于与医疗服务提供者和公共卫生机构合作，扩大推广和教育范围。然而，疫苗接种犹豫、监管障碍和分销物流等挑战可能会限制市场扩张。此外，高昂的研发成本和漫长的核准流程也带来了重大挑战。为了克服这些问题，对无针系统等创新给药技术的投资以及对组合疫苗的研究可能是潜在的成长途径。此外，针对个人免疫系统变化的个人化疫苗可能会彻底改变市场。成人疫苗市场的性质是动态的，受到生物医学不断进步和不断变化的全球健康需求的推动。可持续的业务成长需要相关人员参与强有力的研究和开发，培养更有效的分销管道的伙伴关係，并实施适应策略以应对不断变化的社会需求和监管条件。透过专注于提高疫苗的可用性和效率并投资于促进疫苗快速开发和分配的技术，市场可以克服挑战并抓住成长机会。

主要市场统计
基准年[2023] 176.3亿美元
预测年份 [2024] 191.1亿美元
预测年份 [2030] 307.8亿美元
复合年增长率（%） 8.28%

市场动态：揭示快速发展的成人疫苗市场的关键市场洞察

供需的动态交互作用正在改变成人疫苗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，以及如何减轻消费行为及其对製造成本的影响及其对采购趋势的影响。

波特五力：驾驭成人疫苗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解成人疫苗市场的外部影响

外部宏观环境因素在塑造成人疫苗市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解成人疫苗市场的竞争格局

对成人疫苗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵成人疫苗市场供应商的绩效评估

FPNV定位矩阵是评估成人疫苗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製成人疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，成人疫苗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告提供了涵盖主要焦点细分市场的全面市场分析。

1. 市场渗透率：对当前市场环境的详细回顾。

2. 市场开拓：辨识新兴市场的成长机会，评估现有产业的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检视市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 扩大卫生基础设施和获得疫苗接种服务的机会
      • 预防医学对个人和社区日益重要
      • 新的疫苗可预防疾病和变种的出现
    • 抑制因素
      • 疫苗开发和分销的高成本限制了市场范围
    • 机会
      • 与旅游业相关人员合作，推广旅行疫苗并确保旅行者健康
      • 针对老年族群的综合免疫计划，以提高疫苗接种覆盖率
    • 任务
      • 严格的政府监管和漫长的核准流程阻碍了疫苗市场的扩张
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 成人疫苗市场：依疫苗类型

  • 介绍
  • 灭活疫苗
    • 裂解病毒疫苗
    • 全病毒疫苗
  • 减毒活疫苗
  • 次单位疫苗
    • 多醣体疫苗
    • 蛋白质次单元疫苗
  • 类毒素疫苗

第七章 成人疫苗市场：依适应症分类

  • 介绍
  • B型肝炎
  • 带状疱疹
  • 人类乳突病毒 (HPV)
  • 流感
  • 肺炎链球菌感染

第八章 成人疫苗市场：依最终使用者分类

  • 介绍
  • 诊所
  • 居家医疗
  • 医院
  • 疫苗接种中心

第九章美洲成人疫苗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区成人疫苗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲成人疫苗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-535C6291878F

The Adult Vaccines Market was valued at USD 17.63 billion in 2023, expected to reach USD 19.11 billion in 2024, and is projected to grow at a CAGR of 8.28%, to USD 30.78 billion by 2030.

The adult vaccines market encompasses the development, production, and application of vaccines aimed at preventing infectious diseases in adults. This market addresses the increasing necessity for vaccination due to factors such as the aging global population, rising awareness about preventable diseases, and governmental immunization initiatives. The application scope includes vaccines against influenza, meningitis, HPV, and hepatitis, with end-uses ranging from individual health maintenance to public health programs. Key factors influencing growth include heightened governmental focus on healthcare policies, advances in vaccine technology, and the public's growing awareness of disease prevention. Opportunities abound in emerging markets with low vaccination coverage, where increasing healthcare access can drive growth. Industry players should focus on collaboration with healthcare providers and public health organizations to expand outreach and education. However, challenges such as vaccine hesitancy, regulatory hurdles, and distribution logistics can limit market expansion. Furthermore, high R&D costs and time-consuming approval processes pose significant challenges. To overcome these, investment in innovative delivery technologies, such as needle-free systems, and research into combination vaccines can offer potential growth avenues. Additionally, personalized vaccines that cater to individual immune system variations could revolutionize the market. The nature of the adult vaccine market is dynamic, driven by constant advancements in biomedical science and evolving global health demands. For sustainable business growth, stakeholders should engage in robust R&D, foster partnerships for more effective distribution channels, and implement adaptive strategies to address fluctuating societal needs and regulatory landscapes. By focusing on improving vaccine accessibility and efficiency, and investing in technologies that facilitate rapid vaccine development and distribution, the market can navigate its challenges and harness opportunities for growth.

KEY MARKET STATISTICS
Base Year [2023] USD 17.63 billion
Estimated Year [2024] USD 19.11 billion
Forecast Year [2030] USD 30.78 billion
CAGR (%) 8.28%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Adult Vaccines Market

The Adult Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expansion of healthcare infrastructure and access to vaccination services
    • Growing emphasis on preventive healthcare among individuals and communities
    • Emergence of new vaccine-preventable diseases and variants
  • Market Restraints
    • High costs associated with vaccine development and distribution limit market reach
  • Market Opportunities
    • Collaborations with travel industry stakeholders to promote travel vaccines and ensure traveler health
    • Comprehensive immunization programs targeting the aging population to increase vaccine uptake
  • Market Challenges
    • Stringent government regulations and lengthy approval processes hinder vaccine market expansion

Porter's Five Forces: A Strategic Tool for Navigating the Adult Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Adult Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Adult Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Adult Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Adult Vaccines Market

A detailed market share analysis in the Adult Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Adult Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Adult Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Adult Vaccines Market

A strategic analysis of the Adult Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Adult Vaccines Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca, Bharat Biotech, BioNTech, CSL Limited, CureVac, Dynavax Technologies, Emergent BioSolutions, GlaxoSmithKline, Inovio Pharmaceuticals, Johnson & Johnson, Merck & Co., Moderna, Novavax, Pfizer, Sanofi, Seqirus, Serum Institute of India, Sinovac Biotech, Valneva SE, and Vaxart.

Market Segmentation & Coverage

This research report categorizes the Adult Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Vaccine Type, market is studied across Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, and Toxoid Vaccines. The Inactivated Vaccines is further studied across Split Virus Vaccines and Whole Virus Vaccines. The Subunit Vaccines is further studied across Polysaccharide Vaccines and Protein Subunit Vaccines.
  • Based on Disease Indication, market is studied across Hepatitis B, Herpes Zoster, Human Papillomavirus (HPV), Influenza, and Pneumococcal Disease.
  • Based on End User, market is studied across Clinics, Homecare Settings, Hospitals, and Vaccination Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expansion of healthcare infrastructure and access to vaccination services
      • 5.1.1.2. Growing emphasis on preventive healthcare among individuals and communities
      • 5.1.1.3. Emergence of new vaccine-preventable diseases and variants
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with vaccine development and distribution limit market reach
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborations with travel industry stakeholders to promote travel vaccines and ensure traveler health
      • 5.1.3.2. Comprehensive immunization programs targeting the aging population to increase vaccine uptake
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations and lengthy approval processes hinder vaccine market expansion
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Adult Vaccines Market, by Vaccine Type

  • 6.1. Introduction
  • 6.2. Inactivated Vaccines
    • 6.2.1. Split Virus Vaccines
    • 6.2.2. Whole Virus Vaccines
  • 6.3. Live Attenuated Vaccines
  • 6.4. Subunit Vaccines
    • 6.4.1. Polysaccharide Vaccines
    • 6.4.2. Protein Subunit Vaccines
  • 6.5. Toxoid Vaccines

7. Adult Vaccines Market, by Disease Indication

  • 7.1. Introduction
  • 7.2. Hepatitis B
  • 7.3. Herpes Zoster
  • 7.4. Human Papillomavirus (HPV)
  • 7.5. Influenza
  • 7.6. Pneumococcal Disease

8. Adult Vaccines Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Homecare Settings
  • 8.4. Hospitals
  • 8.5. Vaccination Centers

9. Americas Adult Vaccines Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Adult Vaccines Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Adult Vaccines Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca
  • 2. Bharat Biotech
  • 3. BioNTech
  • 4. CSL Limited
  • 5. CureVac
  • 6. Dynavax Technologies
  • 7. Emergent BioSolutions
  • 8. GlaxoSmithKline
  • 9. Inovio Pharmaceuticals
  • 10. Johnson & Johnson
  • 11. Merck & Co.
  • 12. Moderna
  • 13. Novavax
  • 14. Pfizer
  • 15. Sanofi
  • 16. Seqirus
  • 17. Serum Institute of India
  • 18. Sinovac Biotech
  • 19. Valneva SE
  • 20. Vaxart

LIST OF FIGURES

  • FIGURE 1. ADULT VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. ADULT VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ADULT VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ADULT VACCINES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ADULT VACCINES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ADULT VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ADULT VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ADULT VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ADULT VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ADULT VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ADULT VACCINES MARKET SIZE, BY SPLIT VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ADULT VACCINES MARKET SIZE, BY WHOLE VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ADULT VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ADULT VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ADULT VACCINES MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ADULT VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ADULT VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ADULT VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ADULT VACCINES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ADULT VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. ADULT VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. ADULT VACCINES MARKET, FPNV POSITIONING MATRIX, 2023